Press Release: Elucid Bioimaging Announces Expansion of its Research and Development Team

September 15, 2017

Wenham, Massachusetts – Elucid Bioimaging is pleased to announce the hiring of two key staff to its research and development team. Vladimir Valtchinov, PhD has joined as Director of Software Engineering and Svetlana Egorova, MD, PhD has joined as Clinical Operations Lead.

Dr. Valtchinov, who most recently served as a faculty member at the Center for Evidence Based Imaging (CEBI), a Center of Excellence at the Brigham and Women’s Hospital in Boston, holds a Ph.D. in Theoretical Physics from University of Sofia, Bulgaria. He has extensive experience in large-scale enterprise image, information management, EMR-integrated decision support, translational EHR data warehousing, R&D computation and consumer-oriented web systems. Dr. Valtchinov has published more than 30 papers and international presentations in the fields of clinical decision support, artificial intelligence in imaging and genomics, biophysics, and theoretical condensed matter physics.

“Valdimir is a thought leader in applying advanced statistical, machine learning and AI/deep learning methodologies for building and validating risk assessment and prediction models to support population health stratification, provider and resources utilization for care management, ultimately leading to better value-based patient care” , reflected Andrew Buckler, President and Chief Technology Officer, “He advances Elucid’s increasingly strong contributions in informatics technology in the assessment and realization of stronger value propositions for medical imaging in practice and in research settings.”

Dr. Egorova, also formerly of Brigham and Women’s Hospital where she served as an instructor and faculty member in the MRI Analysis Unit of Partners Multiple Sclerosis Clinical Research Center, holds an MD Physician-Biophysicist specialized in Radiology as well as a PhD in Pharmacology from the Russian State Medical University. She is co-author of numerous papers in the fields of MRI image analysis and neurological disorders.

“Svetlana’s considerable research leadership skills will be invaluable to our efforts to validate the outcomes and cost benefits that vascuCAP® brings to cardiovascular disease care,” remarked John Garber, Chief executive officer, “she will also play an important role in standardizing QA, training and best practices for the users of our software.”

About Elucid Bioimaging Inc.
Elucid is a biomedical engineering company with a unique portfolio of expertise at the crossroads of quantitative medical imaging, clinical trials, surrogate endpoints and big data to enable its Computer Aided Phenotyping® or CAP® diagnostics platform. Elucid’s first commercial product, vascuCAP® has been cleared for sale in the United States and CE marked in Europe for the analysis of atheromatous lesions and their subcomponents from CT angiography data to enhance patient care. The Research Edition is available world-wide for customers performing research.

Contact: Samantha St. Pierre